BR112023005370A2 - Composições e métodos para aumentar função das células-tronco - Google Patents

Composições e métodos para aumentar função das células-tronco

Info

Publication number
BR112023005370A2
BR112023005370A2 BR112023005370A BR112023005370A BR112023005370A2 BR 112023005370 A2 BR112023005370 A2 BR 112023005370A2 BR 112023005370 A BR112023005370 A BR 112023005370A BR 112023005370 A BR112023005370 A BR 112023005370A BR 112023005370 A2 BR112023005370 A2 BR 112023005370A2
Authority
BR
Brazil
Prior art keywords
cell function
stem cell
compositions
methods
enhance stem
Prior art date
Application number
BR112023005370A
Other languages
English (en)
Portuguese (pt)
Inventor
Vannini Nicola
Coukos George
Girotra Mukul
Original Assignee
Nestle Sa
Ludwig Inst For Cancer Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Sa, Ludwig Inst For Cancer Res Ltd filed Critical Nestle Sa
Publication of BR112023005370A2 publication Critical patent/BR112023005370A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112023005370A 2020-09-28 2021-09-28 Composições e métodos para aumentar função das células-tronco BR112023005370A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20198620 2020-09-28
PCT/EP2021/076654 WO2022064061A1 (en) 2020-09-28 2021-09-28 Compositions and methods for increasing stem cell function

Publications (1)

Publication Number Publication Date
BR112023005370A2 true BR112023005370A2 (pt) 2023-05-09

Family

ID=72665073

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023005370A BR112023005370A2 (pt) 2020-09-28 2021-09-28 Composições e métodos para aumentar função das células-tronco

Country Status (8)

Country Link
US (1) US20240010981A1 (cg-RX-API-DMAC7.html)
EP (1) EP4217471A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023543149A (cg-RX-API-DMAC7.html)
CN (1) CN116234900A (cg-RX-API-DMAC7.html)
AU (1) AU2021348257A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023005370A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188629A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022064061A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023237544A1 (en) * 2022-03-22 2024-10-31 Amazentis Sa Compositions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
CZ297278B6 (cs) 1996-08-07 2006-10-11 Darwin Discovery Limited Deriváty hydroxamové a karboxylové kyseliny a jejich pouzití
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
CN101172140B (zh) * 2007-09-11 2011-12-28 珍奥集团股份有限公司 促进造血干细胞增殖与血红蛋白合成的营养组合物
EP2995948A1 (en) * 2014-09-09 2016-03-16 Ecole Polytechnique Federale de Lausanne (EPFL) Methods and compounds useful in hematopoietic stem cell medicine
CN104830772A (zh) * 2015-05-28 2015-08-12 深圳富利鑫健康产业发展有限公司 一种造血干细胞培养基及其应用和干细胞培养方法
EP3393467B1 (en) * 2015-12-24 2020-07-01 Amazentis SA Compositions comprising nicotinamide riboside and a urolithin
CN105838675A (zh) * 2016-06-07 2016-08-10 广东万海细胞生物科技有限公司 一种造血干细胞无血清培养基
US20220241240A1 (en) * 2019-01-18 2022-08-04 Societe Des Produits Nestle S.A. Agents and methods for increasing stem cell function
CN113613663B (zh) * 2019-03-29 2024-09-03 雀巢产品有限公司 用于增加t细胞功能的组合物和方法

Also Published As

Publication number Publication date
EP4217471A1 (en) 2023-08-02
JP2026090303A (ja) 2026-06-02
CN116234900A (zh) 2023-06-06
US20240010981A1 (en) 2024-01-11
AU2021348257A1 (en) 2023-03-02
CA3188629A1 (en) 2022-03-31
WO2022064061A1 (en) 2022-03-31
JP2023543149A (ja) 2023-10-13

Similar Documents

Publication Publication Date Title
BR112021015887A8 (pt) Método para criopreservação de célula-tronco, população de células-tronco, composição de criopreservação, uso de nac, e kit de criopreservação
BR112015020098A2 (pt) método e composição para coloração e processamento de amostras
BR112022004757A2 (pt) Composições de hidrolizado de proteína microbiana e métodos para fazer as mesmas
CL2023001860A1 (es) Composiciones y métodos para reducir hla-a en una célula
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
BR112015001601A2 (pt) células de levedura tendo curso de tca redutor de piruvato em succinato e superexpressão de uma enzima transidrogenase nad(p)+ exógena
BR112022024420A2 (pt) Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas
BR112021017890A2 (pt) Composição líquida compreendendo um anticorpo do receptor alfa de interleucina-4 humana
AR111835A1 (es) Composiciones estables de inoculantes que comprenden aceites vegetales metilados
BR112017011067A2 (pt) cepas e métodos para a partição de energia em ruminantes
BR112015023425A2 (pt) método e composição para coloração e processamento de uma amostra de urina
BR112016027867A2 (pt) composições de fibra e de carboidrato, produto alimentício, métodos para produzir uma composição de fibra, de carboidrato, para reduzir o índice glicêmico e para inibir a elevação do nível de açúcar, composição cosmética, uso da composição de fibra e composição
BR112022001148A2 (pt) Células imunes modificadas, composição farmacêutica, kit, uso de uma célula imune modificada e invenção de produto
BR112014009837A8 (pt) uso eficaz da levedura e extrato de levedura
BR112018015312A2 (pt) cepa fúngica isolada, cultura biologicamente pura, composição inoculante, kit, uso de uma cepa, e, método para aumentar quantidade/concentração de fosfato solúvel em um meio que contém fosfato insolúvel
BR122020001787A8 (pt) Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso
SV2017005416A (es) Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados
BR112013026501A2 (pt) “métodos para preparar um oócito, de fertilização in vitro, e para aumentar a capacidade de geração de atp de um oócito, oócito, e, composição”
BR112022007950A2 (pt) Integração direcionada no locus de alfa-globina em células-tronco e células progenitoras hematopoiéticas humanas
BR112012012960A2 (pt) supositório para administração retal, vaginal ou uretral e seus usos.
CO2026000495A2 (es) Composiciones y métodos para inhibir la expresión de la 3-hidroxi-3-metilglutaril-coa reductasa (hmgcr)
BR112023021840A2 (pt) Método para tratar síndrome da dificuldade respiratória aguda (ards) com o uso de percursor de linhagem mesenquimal ou células-tronco
WO2010059876A3 (en) In vitro human b lymphopoiesis culture system
BR112022019432A2 (pt) Terapia de aumento mitocondrial
CL2025001313A1 (es) Composiciones que contienen enzimas que escinden anticuerpos y métodos de uso de las mismas